Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences, Inc. (NASDAQ: APDN) will announce its fiscal 2021 first quarter financial results on February 11, 2021, after the market closes. A conference call and webcast led by CEO Dr. James A. Hayward, CFO Beth Jantzen, and COO Judith Murrah will follow at 4:30 p.m. ET. The webcast and PowerPoint presentation will be accessible on the company’s website and archived for future viewing. The company specializes in molecular technologies for supply chain security, anti-counterfeiting, and product genotyping.
Applied DNA Sciences (NASDAQ: APDN) has announced the qualification of a lyophilized form of its LinearDNA™ COVID-19 vaccine candidate for feline clinical trials. This freeze-dried formulation enhances shelf stability and simplifies global shipping. The company has manufactured and shipped samples to EvviVax for final preclinical testing, with plans to initiate trials by March 31, 2021. The goal is to evaluate the vaccine's effectiveness in preventing SARS-CoV-2 infections in domestic cats, potentially mitigating transmission risks to humans. Successful trials may lead to a USDA conditional license.
TruTrace Technologies (CSE: TTT) has signed a definitive alliance with Applied DNA Sciences (NASDAQ: APDN) to develop a comprehensive cannabis product validation platform. Combining TruTrace’s StrainSecure™ with Applied DNA’s CertainT® system enables enhanced product authentication and end-to-end traceability through blockchain and molecular tagging. The agreement facilitates mutual referrals and technology integration, enhancing the security of cannabis supply chains. Notably, Shoppers Drug Mart employs TruTrace's platform for its medical cannabis program, underscoring its industry relevance.
Applied DNA Sciences (NASDAQ: APDN) and TruTrace Technologies (CSE: TTT) have formed a strategic alliance to implement a blockchain-based solution for the cannabis industry. The agreement integrates Applied DNA’s CertainT platform with TruTrace’s StrainSecure™ platform, enhancing product validation and authentication. This collaboration aims to ensure end-to-end traceability and transparency, offering significant advantages to consumers and brands against counterfeiting. The partnership also establishes a mutual referral system to capitalize on joint opportunities.
Applied DNA Sciences, Inc. (NASDAQ: APDN) has promoted Judith Murrah from Chief Information Officer to Chief Operating Officer. This position formalizes her growing responsibilities in customer relations, QA oversight, and operations management. Ms. Murrah has played a crucial role in expanding COVID-19 testing and implementing Current Good Manufacturing Practices at LineaRx. With a strong background in technology leadership, Ms. Murrah aims to support the company’s growth in nucleic acid-based therapeutics using its PCR-based LinearDNA™ platform.
Applied DNA Sciences (NASDAQ: APDN) announced that its Linea™ COVID-19 Assay Kit successfully identified COVID-19 variants, including the U.K. variant B.1.1.7, via S-gene dropout. This detection is part of the Company’s safeCircle™ pooled surveillance testing service. The Assay Kit received FDA EUA for identifying SARS-CoV-2 in various respiratory specimens. The Company emphasizes the importance of utilizing its Assay Kit for early detection of new variants to aid in controlling COVID-19 spread. The testing method showcases a multi-target design, maintaining sensitivity even for variant-infected samples.
Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 158% increase in daily average tests for its safeCircle™ pooled surveillance testing service in January 2021 compared to December 2020, due to expanding contracts and new clients.
The Company plans to scale up production of its Linea™ COVID-19 Assay Kit in response to increased demand and recent FDA alerts highlighting its diagnostic capabilities for SARS-CoV-2 mutations. With 33 clients, including educational institutions and local governments, Applied DNA expects to enhance revenue through its CLEARED4 partnership, streamlining COVID-19 testing solutions.
Applied DNA Sciences, Inc. (NASDAQ: APDN) has closed a registered direct offering of 1,810,000 shares of common stock at $8.30 per share, yielding approximately $15 million in gross proceeds. The funds will be used for general corporate purposes, including working capital and advancing the LinearDNA™ manufacturing platform. Roth Capital Partners acted as the sole placement agent for the offering, which was conducted under a shelf registration statement previously filed with the SEC.
Applied DNA Sciences, Inc. (NASDAQ: APDN) has announced a registered direct offering of 1,810,000 shares at $8.30 each, totaling approximately $15 million in gross proceeds. The offering, expected to close on January 13, 2021, aims to support general corporate needs, including research and development and promoting its LinearDNA™ platform. Roth Capital Partners acted as the sole placement agent for this transaction, conducted under a previously effective registration statement.
Applied DNA Sciences announced that its Linea™ COVID-19 Assay Kit is one of only two tests recognized by the FDA for identifying specific SARS-CoV-2 mutations, including the U.K. variant B.1.1.7. This distinction highlights the Assay Kit's multi-target design, which maintains sensitivity despite some genetic variations. The FDA's safety communication indicates that this kit can assist in detecting and tracking COVID-19 variants more effectively. The Assay Kit is authorized for use in various respiratory specimens, aiding public health efforts against COVID-19.
